65,437 trials
Prurigo Nodularis · Pruritis
Primary: Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) Score — -50.6; -29.4; -56.2; -51.0 percentage change — p=0.0347
Liver Cirrhosis
Primary: Area Under the Concentration Time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24) — 94.5; 120.2; 704.6 hours*nanomole/liters (h*nmol/l)
Carcinoma, Non-Small-Cell Lung
Primary: Phase 1: Duration of Exposure of Cabozantinib With Erlotinib — 4.43; 8.14; 8.00; 17.00 Weeks
SARS-CoV-2 Infection · COVID-19
Primary: Number of Participants With Solicited Local Reactions- Post Dose 1 — 30; 30; 29; 30 Participants
Solid Tumor · Lymphoma · Peripheral T-Cell Lymphoma
Primary: Evaluate the Safety and Tolerability of ALRN-6924 in Adult Patients With Advanced Solid Tumors or Lymphomas With Wild-type (WT) TP53 Who Are Refractory to or Intolerant…
Huntington Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 46; 43; 49 Participants
Nasopharyngeal Carcinoma
Primary: Rate of Completion of All Adjuvant Immunotherapy — 100 percentage of participants
Dementia
Primary: Change in Global Cognitive Function as Assessed by the Wechsler Memory Scale-III — -0.2; -0.2 score on a scale
Chronic Insomnia
Primary: Veteran Participants Who Engaged in BBTI — 14; 1; 21; 0 Participants — p=<0.0001
Obesity, Maternal · Hypertension in Pregnancy · Hypertension, Pregnancy-Induced
Primary: Change in Postpartum Weight Retention — -.73; .29 Pounds
Early Breast Cancer · Locally Advanced Breast Cancer · Inflammatory Breast Cancer
Primary: Cross-over Period: Percentage of Participants Who Preferred the Administration of PH FDC SC in the Home Setting Compared With the Hospital Setting in Question 1 of the…
Eating Behavior · Eating Habit
Primary: Change in Brain Response From Baseline to 2-weeks Post High UPF or 2 Weeks no UPF Diet — 0.02; 0.13 arbitrary units
Achilles Tendinopathy
Primary: Calf Raises Performed to Fatigue and Inability to Continue — 3; 8; 5 Calf raises
Arthritis Knee · Aseptic Loosening
Primary: Number of Participants With Successful Application of Bone Cement — 95; 101 Participants
Asthma · Healthy Participants
Primary: Cohort 1: Area Under the Plasma Concentration-time Curve up to 30 Minutes Post- Dose (AUC[0-30]) — 156.41; 162.11 Hour * Picogram per Milliliter (h*pg/mL)